<p>雅培（NYSE:ABT - 获取免费报告）在周三更新了 2025 年第二季度的收益指引。该公司提供的每股收益指引为 1.230-1.270，而市场共识的每股收益预期为 1.250。该公司发布了收入指引为-。雅培还将其 2025 财年的指引更新为每股收益 5.050-5.250。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<h2>雅培股票表现</h2>
<ul>
<li>雅培将在 2025 年超越医疗保健股票</li>
</ul>
<p>雅培股票周三开盘价为 131.09 美元。雅培的 1 年最低价为 99.71 美元，1 年最高价为 141.23 美元。该公司的 50 日移动平均价为 130.62 美元，200 日移动平均价为 121.54 美元。公司的流动比率为 1.60，速动比率为 1.14，债务与股本比率为 0.32。公司的市值为 2273.5 亿美元，市盈率为 17.32，市盈增长比率为 2.52，贝塔值为 0.80。</p>
<p>雅培（NYSE:ABT - 获取免费报告）最近在 4 月 16 日发布了季度收益数据。这家医疗产品制造商报告该季度每股收益为 1.09 美元，超出市场共识预期的 1.07 美元 0.02 美元。雅培的净利润率为 31.95%，股本回报率为 20.74%。该季度的收入为 103.6 亿美元，而市场共识预期为 103.8 亿美元。整体来看，股票研究分析师预测雅培在当前财年将发布 5.14 的每股收益。</p>
<h2>雅培股息公告</h2>
<ul>
<li>这些是值得持有的顶级健康股票</li>
</ul>
<p>该公司最近宣布了一项季度股息，将于 5 月 15 日支付。4 月 15 日的股东将获得每股 0.59 美元的股息。除息日为 4 月 15 日。这代表着年化股息为 2.36 美元，股息收益率为 1.80%。雅培的股息支付比率（DPR）目前为 30.85%。</p>
<h2>分析师评级变动</h2>
<p>多家券商最近对 ABT 发布了报告。巴克莱在 1 月 27 日的研究报告中重申了 “增持” 评级，并将雅培的目标价设定为 158.00 美元（上调自 149.00 美元）。加拿大皇家银行在 1 月 21 日的报告中重申了 “跑赢大盘” 评级，并对雅培的目标价为 135.00 美元。StockNews.com 在 2 月 12 日的研究报告中将雅培的评级从 “强力买入” 下调至 “买入”。花旗在 3 月 4 日的报告中将雅培的目标价从 135.00 美元上调至 160.00 美元，并给予该股票 “买入” 评级。最后，Stifel Nicolaus 在 1 月 23 日的报告中将雅培的目标价从 130.00 美元上调至 135.00 美元，并给予该股票 “买入” 评级。四位投资分析师对该股票给予持有评级，十五位给予买入评级，一位给予强力买入评级。根据 MarketBeat，雅培目前的共识评级为 “适度买入”，平均目标价为 137.94 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 10/14 - 10/18</li>
</ul>
<p><strong>获取我们对雅培的最新股票分析</strong></p>
<h2>雅培的内部买卖</h2>
<p>在其他新闻中，SVP Eric Shroff 在 3 月 3 日的交易中出售了 562 股该公司的股票。股票以 138.17 美元的平均价格出售，总交易额为 77,651.54 美元。交易后，这位高级副总裁现在直接持有 31,970 股公司的股票，价值约为 4,417,294.90 美元。这笔交易代表着他们持股比例减少了 1.73%。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。此外，EVP Andrea F. Wainer 在 3 月 3 日的交易中出售了 949 股雅培的股票。股票以 138.17 美元的平均价格出售，总价值为 131,123.33 美元。出售后，这位执行副总裁现在直接持有 74,381 股公司的股票，价值约为 10,277,222.77 美元。这笔交易代表着他们持股比例减少了 1.26%。该出售的披露可以在这里找到。内部人士在上个季度出售了 116,449 股公司股票，价值 15,463,316 美元。内部人士持有公司股票的比例为 0.46%。</p>
<h2>机构资金流入和流出</h2>
<p>一家对冲基金最近增加了对雅培股票的持股。根据该公司在最近向证券交易委员会提交的文件，Brighton Jones LLC 在第四季度将其在雅培（NYSE:ABT - 免费报告）的持股增加了 10.1%。该基金在此期间购买了额外的 4,755 股后，持有 51,719 股这家医疗产品制造商的股票。Brighton Jones LLC 在雅培的持股在最近的报告期末价值为 5,850,000 美元。75.18% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于雅培</h2>
<p>（获取免费报告）</p>
<p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个部门：已建立的制药产品、诊断产品、营养产品和医疗设备。该公司提供用于治疗胰腺外分泌功能不足、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，超过雅培</li>
<li>什么是热门股票？热门股票解析</li>
<li>黄金反弹持续：这三只矿业股票可能受益</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>XPO 购买 5000 万美元的自家股票：原因在这里</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>特斯拉股票在即将公布财报时瞄准突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

雅培

<p>雅培（NYSE:ABT）更新了其 2025 年第二季度的收益指引，预计每股收益（EPS）在 1.230 到 1.270 之间，略低于市场共识预期的 1.250。该公司还修订了 2025 财年的每股收益指引至 5.050-5.250。雅培的股票开盘价为 131.09 美元，市值为 2273.5 亿美元，市盈率为 17.32。最近的分析师评级显示共识为 “适度买入”，平均目标价为 137.94 美元。该公司宣布每股季度分红为 0.59 美元，将于 5 月 15 日支付</p>

<p>Abbott Laboratories (NYSE:ABT - Get Free Report) updated its second quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.230-1.270 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2025 guidance to 5.050-5.250 EPS.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）在周三更新了 2025 年第二季度的收益指引。该公司提供的每股收益指引为 1.230-1.270，而市场共识的每股收益预期为 1.250。该公司发布了收入指引为-。雅培还将其 2025 财年的指引更新为每股收益 5.050-5.250。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表现</h2>
</div><ul>
<li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培将在 2025 年超越医疗保健股票</li>
</ul>
</div><p>Shares of Abbott Laboratories stock opened at $131.09 on Wednesday. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The company has a 50 day moving average of $130.62 and a 200-day moving average of $121.54. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a market cap of $227.35 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80.</p>
<div class="lb-trans"><p>雅培股票周三开盘价为 131.09 美元。雅培的 1 年最低价为 99.71 美元，1 年最高价为 141.23 美元。该公司的 50 日移动平均价为 130.62 美元，200 日移动平均价为 121.54 美元。公司的流动比率为 1.60，速动比率为 1.14，债务与股本比率为 0.32。公司的市值为 2273.5 亿美元，市盈率为 17.32，市盈增长比率为 2.52，贝塔值为 0.80。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近在 4 月 16 日发布了季度收益数据。这家医疗产品制造商报告该季度每股收益为 1.09 美元，超出市场共识预期的 1.07 美元 0.02 美元。雅培的净利润率为 31.95%，股本回报率为 20.74%。该季度的收入为 103.6 亿美元，而市场共识预期为 103.8 亿美元。整体来看，股票研究分析师预测雅培在当前财年将发布 5.14 的每股收益。</p>
</div><h2>Abbott Laboratories Dividend Announcement</h2>
<div class="lb-trans"><h2>雅培股息公告</h2>
</div><ul>
<li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>这些是值得持有的顶级健康股票</li>
</ul>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.80%. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.85%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度股息，将于 5 月 15 日支付。4 月 15 日的股东将获得每股 0.59 美元的股息。除息日为 4 月 15 日。这代表着年化股息为 2.36 美元，股息收益率为 1.80%。雅培的股息支付比率（DPR）目前为 30.85%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages have recently issued reports on ABT. Barclays restated an &#34;overweight&#34; rating and set a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Royal Bank of Canada restated an &#34;outperform&#34; rating and issued a $135.00 target price on shares of Abbott Laboratories in a report on Tuesday, January 21st. StockNews.com lowered Abbott Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday, February 12th. Citigroup increased their price target on Abbott Laboratories from $135.00 to $160.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, March 4th. Finally, Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Abbott Laboratories presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $137.94.</p>
<div class="lb-trans"><p>多家券商最近对 ABT 发布了报告。巴克莱在 1 月 27 日的研究报告中重申了 “增持” 评级，并将雅培的目标价设定为 158.00 美元（上调自 149.00 美元）。加拿大皇家银行在 1 月 21 日的报告中重申了 “跑赢大盘” 评级，并对雅培的目标价为 135.00 美元。StockNews.com 在 2 月 12 日的研究报告中将雅培的评级从 “强力买入” 下调至 “买入”。花旗在 3 月 4 日的报告中将雅培的目标价从 135.00 美元上调至 160.00 美元，并给予该股票 “买入” 评级。最后，Stifel Nicolaus 在 1 月 23 日的报告中将雅培的目标价从 130.00 美元上调至 135.00 美元，并给予该股票 “买入” 评级。四位投资分析师对该股票给予持有评级，十五位给予买入评级，一位给予强力买入评级。根据 MarketBeat，雅培目前的共识评级为 “适度买入”，平均目标价为 137.94 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 10/14 - 10/18</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 10/14 - 10/18</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>获取我们对雅培的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at Abbott Laboratories</h2>
<div class="lb-trans"><h2>雅培的内部买卖</h2>
</div><p>In other news, SVP Eric Shroff sold 562 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the transaction, the senior vice president now directly owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This trade represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $131,123.33. Following the sale, the executive vice president now directly owns 74,381 shares of the company's stock, valued at approximately $10,277,222.77. This trade represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 over the last quarter. Insiders own 0.46% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，SVP Eric Shroff 在 3 月 3 日的交易中出售了 562 股该公司的股票。股票以 138.17 美元的平均价格出售，总交易额为 77,651.54 美元。交易后，这位高级副总裁现在直接持有 31,970 股公司的股票，价值约为 4,417,294.90 美元。这笔交易代表着他们持股比例减少了 1.73%。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。此外，EVP Andrea F. Wainer 在 3 月 3 日的交易中出售了 949 股雅培的股票。股票以 138.17 美元的平均价格出售，总价值为 131,123.33 美元。出售后，这位执行副总裁现在直接持有 74,381 股公司的股票，价值约为 10,277,222.77 美元。这笔交易代表着他们持股比例减少了 1.26%。该出售的披露可以在这里找到。内部人士在上个季度出售了 116,449 股公司股票，价值 15,463,316 美元。内部人士持有公司股票的比例为 0.46%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A hedge fund recently raised its stake in Abbott Laboratories stock. Brighton Jones LLC raised its position in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 51,719 shares of the healthcare product maker's stock after buying an additional 4,755 shares during the period. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 at the end of the most recent reporting period. 75.18% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了对雅培股票的持股。根据该公司在最近向证券交易委员会提交的文件，Brighton Jones LLC 在第四季度将其在雅培（NYSE:ABT - 免费报告）的持股增加了 10.1%。该基金在此期间购买了额外的 4,755 股后，持有 51,719 股这家医疗产品制造商的股票。Brighton Jones LLC 在雅培的持股在最近的报告期末价值为 5,850,000 美元。75.18% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>关于雅培</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个部门：已建立的制药产品、诊断产品、营养产品和医疗设备。该公司提供用于治疗胰腺外分泌功能不足、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>XPO Buying $50 Million of Its Own Stock: Here's Why</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Tesla Stock Eyes Breakout With Earnings on Deck</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，超过雅培</li>
<li>什么是热门股票？热门股票解析</li>
<li>黄金反弹持续：这三只矿业股票可能受益</li>
<li>特殊目的收购公司（SPAC）你需要知道的事项</li>
<li>XPO 购买 5000 万美元的自家股票：原因在这里</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>特斯拉股票在即将公布财报时瞄准突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

雅培（NYSE:ABT）发布 2025 年第二季度的收益指引